Look, M P <br/><br/>
Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease.  [electronic resource] 

 -  AIDS research and human retroviruses  Sep 2000 
 - 1215-21 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0889-2229 
<br/><br/><label>Standard No.: </label>10.1089/08892220050116989  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anti-HIV Agents--therapeutic use<br/>Antigens, CD--blood<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--physiology<br/>Humans<br/>Kynurenine--blood<br/>Male<br/>Middle Aged<br/>Quinolinic Acid--blood<br/>RNA, Viral--blood<br/>Receptors, Tumor Necrosis Factor--blood<br/>Receptors, Tumor Necrosis Factor, Type II<br/>Reverse Transcriptase Inhibitors--therapeutic use<br/>Treatment Outcome<br/>Tryptophan--blood<br/>Viral Load